Nasdaq · CIK 0001357459
PALI PALISADE BIO, INC.
Insider trading from SEC Form 4. Last filing 5 d ago. Close $1.54 on Oct 9, 2026, +14% from the 52-week low and -45% from the high.
Last 90 days
Net insider value
+$29k
more bought than sold
Buys
1
$29k by 1 insider
Sells
0
$0 by 0 insiders
Insiders on file
5
with a Form 4 at this company
Price and insider trades, last year
PALIOct 9, 2026 · close 1.54
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at PALISADE BIO, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | Donald Allen Williams director buy | $29k 20,000 shares | +1% | - |
Transactions
The last 22 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Mitchell Lawrence Jones See Remarks | MOption exercise Common Stock | +2,620,850 | - | - | 2,714,859 | 5 d ago |
| Oct 6, 2026 | John David Finley CEO CFO | MOption exercise Common Stock | +3,227,384 | - | - | 3,356,672 | 5 d ago |
| Oct 6, 2026 | John David Finley CEO CFO | FTax withholding Common Stock | -1,411,982 | $1.49 | $2.1M | 1,944,690 | 5 d ago |
| Oct 6, 2026 | Mitchell Lawrence Jones See Remarks | FTax withholding Common Stock | -1,031,102 | $1.49 | $1.5M | 1,683,757 | 5 d ago |
| Oct 6, 2026 | Mitchell Lawrence Jones See Remarks | MOption exercise Restricted Stock Unitsderivative | -2,555,266 | $0.00 | $0 | 5,110,534 | 5 d ago |
| Oct 6, 2026 | John David Finley CEO CFO | MOption exercise Restricted Stock Unitsderivative | -3,059,800 | $0.00 | $0 | 6,119,600 | 5 d ago |
| Oct 6, 2026 | Mitchell Lawrence Jones See Remarks | MOption exercise Restricted Stock Unitsderivative | -65,584 | $0.00 | $0 | 590,249 | 5 d ago |
| Oct 6, 2026 | John David Finley CEO CFO | MOption exercise Restricted Stock Unitsderivative | -167,584 | $0.00 | $0 | 1,508,249 | 5 d ago |
| Oct 1, 2026 | Donald Allen Williams director | POpen-market purchase Common Stock | +10,000 | $1.42 | $14k | 1,580,294 | 7 d ago |
| Oct 2, 2026 | Donald Allen Williams director | POpen-market purchase Common Stock | +10,000 | $1.46 | $15k | 1,590,294 | 7 d ago |
| Sep 4, 2025 | John David Finley CEO, CFO | AGrant or award Phantom Unitsderivative | +323,400 | $0.00 | $0 | 323,400 | Sep 5, 2025 |
| Sep 4, 2025 | Donald Allen Williams director | AGrant or award Phantom Unitsderivative | +64,400 | $0.00 | $0 | 64,400 | Sep 5, 2025 |
| Sep 4, 2025 | Binxian Wei director | AGrant or award Phantom Unitsderivative | +18,800 | $0.00 | $0 | 18,800 | Sep 5, 2025 |
| Sep 4, 2025 | Mitchell Lawrence Jones Chief Medical Officer | AGrant or award Phantom Unitsderivative | +289,000 | $0.00 | $0 | 289,000 | Sep 5, 2025 |
| Sep 4, 2025 | Emil Chuang director | AGrant or award Phantom Unitsderivative | +18,800 | $0.00 | $0 | 18,800 | Sep 5, 2025 |
| Jul 18, 2025 | Emil Chuang director | AGrant or award Stock Option (Right to Buy)derivative | +8,000 | $0.00 | $0 | 8,000 | Jul 22, 2025 |
| Feb 11, 2025 | John David Finley CEO, CFO | AGrant or award Stock Option (Right to Buy)derivative | +47,000 | $0.00 | $0 | 47,000 | Feb 13, 2025 |
| Feb 11, 2025 | Mitchell Lawrence Jones Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +29,000 | $0.00 | $0 | 29,000 | Feb 13, 2025 |
| Feb 11, 2025 | John David Finley CEO, CFO | AGrant or award Restricted Stock Unitsderivative | +40,000 | $0.00 | $0 | 40,000 | Feb 13, 2025 |
| Feb 11, 2025 | Mitchell Lawrence Jones Chief Medical Officer | AGrant or award Restricted Stock Unitsderivative | +24,000 | $0.00 | $0 | 24,000 | Feb 13, 2025 |
| Nov 21, 2024 | Donald Allen Williams director | MOption exercise Comon Stock, par value $0.01 | +388 | $0.00 | $0 | 728 | Nov 22, 2024 |
| Nov 21, 2024 | Binxian Wei director | MOption exercise Comon Stock, par value $0.01 | +388 | $0.00 | $0 | 855 | Nov 22, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Emil Chuangdirector
- John David FinleyCEO, CFO
- Mitchell Lawrence JonesChief Medical Officer
- Binxian Weidirector
- Donald Allen Williamsdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.